Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-114 in combination with subcutaneous (SC) amivantamab in patients with advanced or metastatic NSCLC harboring an EGFR exon 20 insertion mutation.

Participants needed: 76
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: ORIC PharmaceuticalsUpdated: Apr 24, 2026Locations: 4
Eligibility criteria

Histologically or cytologically confirmed metastatic NSCLC with a documented EGF... [+7]

Known small cell lung cancer transformation [+5]

Read more
Status: Recruiting

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.

Participants needed: 250
Trial details
Phase: Phase 1Age: 18+Biological sex: MaleType: InterventionalSponsor: ORIC PharmaceuticalsUpdated: Aug 11, 2025Locations: 27
Eligibility criteria

Patients with metastatic prostate cancer [+10]

History or presence of CNS metastases, unless previously treated and stable [+5]

Read more
Status: Recruiting

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or HER2 alteration.

Participants needed: 350
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: ORIC PharmaceuticalsUpdated: Aug 5, 2025Locations: 42
Eligibility criteria

Histologically or cytologically confirmed locally advanced or metastatic solid t... [+20]

Known EGFR T790M mutation [+7]

Read more